A model to predict the cost-effectiveness of disease management programs

Health Economics

Volumn 19, Issue 6, 2010, Pages 697-715

  Gandjour, Afschin ^a,b  

^a RICE UNIVERSITY   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Decision support technique; Disease management; Health care costs

Indexed keywords

ARTICLE; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE MANAGEMENT; HEALTH CARE COST; HEALTH PROGRAM; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL;

AGED; CHRONIC DISEASE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE MANAGEMENT; FEMALE; FORECASTING; GERMANY; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY OF HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS;

EID: 77952774321     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1503     Document Type: Article

References (61)

1. Anderson KM, Odell PM, Wilson PWF, Kannel WB. 1990. Cardiovascular disease risk profiles. American Heart Journal 121: 293-298.
2. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR. Writing Group of the PREMIER Collaborative Research Group. 2003. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. The Journal of the American Medical Association 289: 2083-2093.
3. Arnesen T, Trommald M. 2004. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. Journal of Health Services Research and Policy 9: 43-50. (Pubitemid 38166453)
4. Arzneimittelkommission der deutschen Ärzteschaft. Koronare Herzkrankheit [online]. http://www.akdae.de/35/10Hefte/76-KHK-2004-1Auflage.pdf [accessed 2005 July 24].
5. Bronnum-Hansen H, Jorgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, Schroll M. 2001. Survival and cause of death after myocardial infarction: the Danish MONICA study. Journal of Clinical Epidemiology 54: 1244-1250. (Pubitemid 34002977)
6. Bundesärztekammer. Ärztestatistik [online]. http://www.bundesaerztekammer.de/downloads/Aerztestatistik-04-Abb-2- Berufstaetige-nach-Arztgruppen.pdf [accessed 2009 May 22].
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. 2003. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Journal of the American Medical Association 289: 2560-2572.
8. Disease Management Association of America. Definition of Disease Management [online]. http://www.dmaa.org/ [accessed 2007 September 9].
9. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. 1995. Endarterectomy for asymptomatic carotid artery stenosis. Journal of the American Medical Association 273: 1421-1428.
10. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. 2004. Predictors of new-onset kidney disease in a community-based population. Journal of the American Medical Association 291: 844-850. (Pubitemid 38543772)
11. Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland [online]. http://www.quasi-niere.de/ [accessed 2006 December 23].
12. Fretheim A, Aaserud M, Oxman AD. 2003. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Services Research 3: 18. (Pubitemid 38783270)
13. Gage BF, Cardinalli AB, Albers GW, Owens DK. 1995. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. Journal of the American Medical Association 274: 1839-1845.
14. Gandjour A, Lauterbach KW. 2003. When is it worth introducing a quality improvement program? A mathematical model. Medical Decision Making 23: 518-525. (Pubitemid 37448917)
15. Gandjour A, Lauterbach KW. 2004. When is it worth reducing underuse and overuse of medical services? The example of treating acute depression (in German). Psychiatrische Praxis 31: 157-162.
16. Gandjour A, Lauterbach KW. 2005. How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing. Medical Decision Making 25: 341-347. (Pubitemid 40696283)
17. Gandjour A, Stock S. 2007. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 83: 257-267. (Pubitemid 47259206)
18. Gasse C, Hense HW, Stieber J, Doring A, Liese AD, Heller G, Keil U. 2002. Factors associated with differences in antihypertensive drug treatment: results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95. Sozial-und Präventivmedizin 47: 128-142.
19. Göhler A, Januzzi JL, Worrell SS, Osterziel KJ, Gazelle GS, Dietz R, Siebert U. 2006. A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. Journal of Cardiac Failure 12: 554-567. (Pubitemid 44307702)
20. Gold M, Seigel J Russell L, Weinstein M. 1996. Cost-effectiveness in Health and Medicine. Oxford University Press: New York.
21. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, Eccles MP, Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C. 2004. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment 8(6): iii-iv, 1-72.
22. Grol R. 2001. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Medical Care 39(8 Suppl 2): II46-II54.
23. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. 2003. Ten-year survival after first-ever stroke in the perth community stroke study. Stroke 34: 1842-1846. (Pubitemid 36944765)
24. Hasford J, Mimran A, Simons WR. 2002. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. Journal of Human Hypertension 16: 569-575. (Pubitemid 35021364)
25. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. 2003. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. European Heart Journal 24: 937-945. (Pubitemid 36559987)
26. Hoffman C, Rice D, Sung HY. 1996. Persons with chronic conditions. Their prevalence and costs. The Journal of the American Medical Association 276: 1473-1479. (Pubitemid 26398755)
27. Hughes D, Cowell W, Koncz T, Cramer J. 2007. International Society for Pharmacoeconomics and Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value in Health 10(6): 498-509.
28. Hysong SJ, Best RG, Pugh JA. 2006. Audit and feedback and clinical practice guideline adherence: making feedback actionable. Implementation Science 28: 9.
29. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. 2006. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews 2: CD000259.
30. Kassenärztliche Bundesvereinigung Berlin. Einheitlicher Bewertungsma Xstab für ärztliche Leistungen. Berlin, 2006.
31. Kassenärztliche Vereinigung Nord-Württemberg. Übersicht zur Abrechnung und Vergütung der Betreuung und Schulung von Diabetes-Patienten (date: 2003 October 1) [online]. http://www.kvnw.de/home/ rechtsquellen/vertraege/dmp-vertrag%5CDMPVerguetungsuebersicht.pdf [accessed 2004 April 24].
32. Marton KI, Tul V, Sox Jr HC. 1985. Modifying test-ordering behavior in the outpatient medical clinic. A controlled trial of two educational interventions. Archives of Internal Medicine 145: 816-821.
33. Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M. 2001. When is it cost-effective to change the behavior of health professionals? The Journal of the American Medical Association 286: 2988-2992.
34. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA. 2003. The quality of health care delivered to adults in the United States. The New England Journal of Medicine 348: 2635-2645. (Pubitemid 36741592)
35. MONICA/KORA-Herzinfarktregister Augsburg [online]. http://www.gbe-bund.de [accessed 2005 August 2].
36. Mullins CD, Sikirica M, Seneviratne V, Ahn J, Akhras KS. 2004. Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 22: 1001-1014. (Pubitemid 39472625)
37. Neal B, MacMahon S, Chapman N. 2000. Blood pressure lowering treatment trialists' collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 56: 1955-1964.
38. Nebel M. 2002. Behandlungskosten der Nierenersatztherapie in Deutschland 1999. Nieren- und Hochdruckkrankheiten 3: 85-92.
39. Oßwald H, Mühlbauer B. 2004. Diuretika. In Arzneiverordnungsreport, 2003, Schwabe U, Paffrath D (eds). Springer: Berlin, Heidelberg.
40. Ofman JJ, Badamgarav E, Henning JM, Knight K, Gano Jr AD, Levan RK, Gur-Arie S, Richards MS, Hasselblad V, Weingarten SR. 2004. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. The American Journal of Medicine 117: 182-192. (Pubitemid 39055870)
41. Pickering TG. 2003. Lifestyle modification and blood pressure control: is the glass half full or half empty? The Journal of the American Medical Association 289: 2131-2132.
42. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. 2003. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. The Journal of the American Medical Association 289: 2534-2544. (Pubitemid 37430155)
43. Peterson AM, Takiya L, Finley R. 2003. Meta-analysis of trials of interventions to improve medication adherence. American Journal of Health-System Pharmacy 60: 657-665. (Pubitemid 36752868)
44. Porsch-Özçürümez MK. Vergleichende Untersuchung der Lipidstoffwechselparameter zwischen 35-64 jährigen deutschen und in Deutschland lebenden türkischen Teilnehmern einer Gesundheitsvorsorgeuntersuchung (Check-up 35) [dissertation]. Justus-Liebig-Universität Gießen: Gießen; 1997.
45. Rote Liste Service GmbH. Rote Liste: Arzneimittelverzeichnis für Deutschland [online]. http://www.rote-liste.de [accessed 2006 August 4].
46. Selbstverwaltung für German Refined-Diagnosis Related Groups. G-DRG V2005 Browser 2004 [online]. http://www.g-drg.de/ [accessed 2006 December 29].
47. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, Lehnert H, Tschope D, Krause P, Hofler M, Pfister H, Bramlage P, Unger T, HYDRA Study Group. 2004. High prevalence and poor control of hypertension in primary care: cross-sectional study. Journal of Hypertension 22: 479-486. (Pubitemid 38368480)
48. Spitzenverbände der Krankenkassen. Vereinbarung der Spitzenverbände der am RSA-beteiligten Krankenkassen gem. § 267 Abs. 7 SGB V (date: 2003 April 29) [online]. http://www.bva.de/Fachinformationen/ Risikostrukturausgleich/Informationen/ [accessed 2004 April 24].
49. Statistisches Bundesamt 2004. Krankheitskosten 2002. Statistisches Bundesamt: Wiesbaden.
50. Statistisches Bundesamt. Anzahl der Sterbefälle (ab 1998. Region, Alter, Geschlecht, Nationalität, ICD-10) [online]. http://www.gbe-bund.de/ [accessed 2005 December 1].
51. Thamm M. 1999. Blood pressure in Germany - current status and trends. Gesundheitswesen 61: S90-S93.
52. Thefeld W. 2000. Verbreitung der Herz-Kreislauf-Risikofaktoren Hypercholesterinämie, Übergewicht, Hypertonie und Rauchen in der Bevölkerung. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 43: 415-423
53. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. 1993. Stability of time-tradeoff utilities in survivors of myocardial infarction. Medical Decision Making 13: 161-165. (Pubitemid 23113453)
54. Universität Erlangen-Nürnberg. Schlaganfall in Deutschland (date: 2003) [online]. http://www.dsg-info.de/pdf/Anhaltszahlen-zum- Schlaganfall.pdf [accessed 2008 September 1].
55. Villagra V. 2004. Strategies to control costs and quality: a focus on outcomes research for disease management. Medical Care 42(4 Suppl): III24-III30.
56. Wiesner G, Grimm J, Bittner E. 1999a. Incidence of myocardial infarct in Germany: prevalence, incidence trends, east-west comparison. Gesundheitswesen 61: S72-S78.
57. Wiesner G, Grimm J, Bittner E. 1999b. Stroke: prevalence, incidence, trends, East-West comparison. Initial results of the 1998 Federal Health Survey. Gesundheitswesen 61: S79-S84.
58. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ, Second Australian National Blood Pressure Study Group. 2003. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. The New England Journal of Medicine 348: 583-592.
59. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. 2003. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Journal of the American Medical Assocation 289: 2363-2369. (Pubitemid 37430168)
60. Wolfe CD, Giroud M, Kolominsky-Rabas P, Dundas R, Lemesle M, Heuschmann P, Rudd A. 2000. Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. Stroke 31: 2074-2079.
61. Zentralinstitut für die kassenärztliche Versorgung. 2001. Patienten-Arzt-Panel (ADT-Panel) zur Morbiditätsanalyse. ZI: Köln: Berlin.